LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Harenberg, Job"
  2. AU="Bradfield, Owen"
  3. AU=Parmegiani Lodovico
  4. AU=Nasmyth Kim AU=Nasmyth Kim
  5. AU=Krumm Brian AU=Krumm Brian
  6. AU="Isojima, Tsuyoshi"
  7. AU="Rioufol, Gilles"
  8. AU="Hiesmayr, B. C."
  9. AU="Qudrat-Ullah, Hassan"
  10. AU=Kim Ginah Lee
  11. AU="Jeannin, Anne-Caroline"

Suchergebnis

Treffer 1 - 10 von insgesamt 227

Suchoptionen

  1. Buch ; Konferenzbeitrag: Basic and clinical considerations of heparins / 2

    Harenberg, Job

    [5th Glycosaminoglycan Symposium at Villa Vigoni at Lake Como in Italy, held September 16 to 18, 1996]

    (... ; 23,2)

    1997  

    Veranstaltung/Kongress Glycosaminoglycan Symposium (5, 1996)
    Verfasserangabe Job Harenberg, guest ed
    Serientitel ... ; 23,2
    Seminars in thrombosis and hemostasis
    Basic and clinical considerations of heparins
    Überordnung Seminars in thrombosis and hemostasis
    Basic and clinical considerations of heparins
    Sprache Englisch
    Umfang S. 97 - 233 : Ill., graph. Darst.
    Verlag Thieme
    Erscheinungsort New York u.a.
    Erscheinungsland Vereinigte Staaten
    Dokumenttyp Buch ; Konferenzbeitrag
    HBZ-ID HT007960637
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Kategorien

  2. Buch ; Konferenzbeitrag: Basic and clinical considerations of heparins / 1

    Harenberg, Job

    [5th Glycosaminoglycan Symposium at Villa Vigoni at Lake Como in Italy, held September 16 to 18, 1996]

    (... ; 23,1)

    1997  

    Veranstaltung/Kongress Glycosaminoglycan Symposium (5, 1996)
    Verfasserangabe Job Harenberg, guest ed
    Serientitel ... ; 23,1
    Seminars in thrombosis and hemostasis
    Basic and clinical considerations of heparins
    Überordnung Seminars in thrombosis and hemostasis
    Basic and clinical considerations of heparins
    Sprache Englisch
    Umfang S. 1 - 96 : graph. Darst.
    Verlag Thieme
    Erscheinungsort New York u.a.
    Erscheinungsland Vereinigte Staaten
    Dokumenttyp Buch ; Konferenzbeitrag
    HBZ-ID HT007922245
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Kategorien

  3. Buch ; Konferenzbeitrag: Nonanticoagulant actions of glycosaminoglycans

    Harenberg, Job

    [proceedings of the Fourth Symposium on Glycosaminoglycans: Nonanticoagulant Actions of Glycosaminoglycans - Results and Perspectives of the German-Italian Collaboration held October 6 - 8, 1994, in Loveno, Italy]

    1996  

    Körperschaft Symposium on Glycosaminoglycans
    Verfasserangabe ed. by Job Harenberg
    Schlagwörter Glycosaminoglycans / pharmacology / congresses ; Glycosaminoglycans / therapeutic use / congresses ; Anticoagulants / pharmacology / congresses ; Glykosaminoglykane ; Arzneimittel ; Antikoagulans ; Pharmakologie ; Thrombose ; Prävention
    Schlagwörter Glykosaminglykane ; Glycosaminoglycane ; Glycosaminglycane ; Mucopolysaccharide ; Arzneimittellehre ; Arzneimittelwirkung ; Arzneiwirkung ; Experimentelle Pharmakologie ; Anticoagulans ; Gerinnungshemmendes Mittel ; Gerinnungshemmer ; Blutgerinnungshemmendes Mittel ; Thrombininhibitor ; Blutgerinnungshemmer ; Fertigarzneimittel ; Therapeutikum ; Medikament ; Medukamente ; Pharmakon ; Pharmaka ; Arzneistoff ; Arzneimittelwirkstoff ; Arznei ; Pharmazeutikum ; Pharmazeutika ; Pharmazeutischer Wirkstoff ; Arzneidroge ; Verhütung ; Vorbeugung ; Prophylaxe ; Vorsorge ; Thrombosen
    Sprache Englisch
    Umfang VIII, 295 S. : zahlr. graph. Darst.
    Verlag Plenum Press
    Erscheinungsort New York u.a.
    Erscheinungsland Vereinigte Staaten
    Dokumenttyp Buch ; Konferenzbeitrag
    HBZ-ID HT007467029
    ISBN 0-306-45299-5 ; 978-0-306-45299-4
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Kategorien

  4. Artikel ; Online: COVID-19 and Long-COVID Thrombosis: From Clinical and Basic Science to Therapeutics.

    Violi, Francesco / Harenberg, Job / Pignatelli, Pasquale / Cammisotto, Vittoria

    Thrombosis and haemostasis

    2023  Band 124, Heft 4, Seite(n) 286–296

    Abstract: Coronavirus infectious disease-19 (COVID-19) is a pandemic characterized by serious lung disease and thrombotic events in the venous and circulation trees, which represent a harmful clinical sign of poor outcome. Thrombotic events are more frequent in ... ...

    Abstract Coronavirus infectious disease-19 (COVID-19) is a pandemic characterized by serious lung disease and thrombotic events in the venous and circulation trees, which represent a harmful clinical sign of poor outcome. Thrombotic events are more frequent in patients with severe disease requiring intensive care units and are associated with platelet and clotting activation. However, after resolution of acute infection, patients may still have clinical sequelae, the so-called long-COVID-19, including thrombotic events again in the venous and arterial circulation. The mechanisms accounting for thrombosis in acute and long COVID-19 have not been fully clarified; interactions of COVID-19 with angiotensin converting enzyme 2 or toll-like receptor family or infection-induced cytokine storm have been suggested to be implicated in endothelial cells, leucocytes, and platelets to elicit clotting activation in acute as well in chronic phase of the disease. In acute COVID-19, prophylactic or full doses of anticoagulants exert beneficial effects even if the dosage choice is still under investigation; however, a residual risk still remains suggesting a need for a more appropriate therapeutic approach. In long COVID-19 preliminary data provided useful information in terms of antiplatelet treatment but definition of candidates for thrombotic prophylaxis is still undefined.
    Mesh-Begriff(e) Humans ; COVID-19 ; Post-Acute COVID-19 Syndrome ; Endothelial Cells ; SARS-CoV-2 ; Anticoagulants/therapeutic use ; Thrombosis/drug therapy ; Communicable Diseases
    Chemische Substanzen Anticoagulants
    Sprache Englisch
    Erscheinungsdatum 2023-11-15
    Erscheinungsland Germany
    Dokumenttyp Journal Article
    ZDB-ID 518294-3
    ISSN 2567-689X ; 0340-6245
    ISSN (online) 2567-689X
    ISSN 0340-6245
    DOI 10.1055/s-0043-1776713
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Buch ; Konferenzbeitrag: Glycosaminoglycans / 1

    Harenberg, Job

    [selected from presentations given at a workshop in Loveno di Menagio, Italy, in May 1993]

    (... ; 20,2)

    1994  

    Verfasserangabe Job Harenberg ... [eds.]
    Serientitel ... ; 20,2
    Glycosaminoglycans
    Überordnung Glycosaminoglycans
    Sprache Englisch
    Umfang S. 133 - 222 : Ill., graph. Darst.
    Verlag Thieme
    Erscheinungsort New York u.a.
    Erscheinungsland Vereinigte Staaten
    Dokumenttyp Buch ; Konferenzbeitrag
    HBZ-ID HT006629101
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Kategorien

  6. Buch ; Konferenzbeitrag: Glycosaminoglycans / 2

    Harenberg, Job

    [selected from presentations given at a workshop in Loveno di Menagio, Italy, in May 1993]

    (... ; 20,3)

    1994  

    Verfasserangabe Job Harenberg ... [eds.]
    Serientitel ... ; 20,3
    Glycosaminoglycans
    Überordnung Glycosaminoglycans
    Sprache Englisch
    Umfang S. 227 - 309 : graph. Darst.
    Verlag Thieme
    Erscheinungsort New York u.a.
    Erscheinungsland Vereinigte Staaten
    Dokumenttyp Buch ; Konferenzbeitrag
    HBZ-ID HT006591498
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Kategorien

  7. Artikel ; Online: Anticoagulant Treatment of COVID-19 as Early as Possible-Sulodexide and Perspectives.

    Schulman, Sam / Harenberg, Job

    Thrombosis and haemostasis

    2021  Band 121, Heft 7, Seite(n) 849–853

    Mesh-Begriff(e) Anticoagulants ; COVID-19 ; Glycosaminoglycans ; Humans ; SARS-CoV-2
    Chemische Substanzen Anticoagulants ; Glycosaminoglycans ; glucuronyl glucosamine glycan sulfate (75HGV0062C)
    Sprache Englisch
    Erscheinungsdatum 2021-06-15
    Erscheinungsland Germany
    Dokumenttyp Editorial ; Comment
    ZDB-ID 518294-3
    ISSN 2567-689X ; 0340-6245
    ISSN (online) 2567-689X
    ISSN 0340-6245
    DOI 10.1055/a-1477-3569
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: Waves of SARS-CoV-2 Infection and Blood Coagulation-A Link and Beyond.

    Harenberg, Job / Violi, Francesco

    Thrombosis and haemostasis

    2021  Band 121, Heft 1, Seite(n) 4–6

    Mesh-Begriff(e) Anticoagulants/therapeutic use ; Blood Coagulation/drug effects ; COVID-19/blood ; COVID-19/drug therapy ; COVID-19/mortality ; COVID-19/virology ; Host-Pathogen Interactions ; Humans ; SARS-CoV-2/pathogenicity ; Thromboembolism/blood ; Thromboembolism/mortality ; Thromboembolism/prevention & control ; Thromboembolism/virology
    Chemische Substanzen Anticoagulants
    Sprache Englisch
    Erscheinungsdatum 2021-01-21
    Erscheinungsland Germany
    Dokumenttyp Editorial
    ZDB-ID 518294-3
    ISSN 2567-689X ; 0340-6245
    ISSN (online) 2567-689X
    ISSN 0340-6245
    DOI 10.1055/s-0040-1721778
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: Past, present, and future perspectives of heparins in clinical settings and the role of impaired renal function.

    Harenberg, Job

    International journal of cardiology

    2016  Band 212 Suppl 1, Seite(n) S10–3

    Abstract: Heparin, whose discovery goes back one hundred years, was first detected as a thromboplastin from liver tissue, and its anticoagulant action was only identified later. The procoagulant action of heparin, which was later characterized as an immunologic ... ...

    Abstract Heparin, whose discovery goes back one hundred years, was first detected as a thromboplastin from liver tissue, and its anticoagulant action was only identified later. The procoagulant action of heparin, which was later characterized as an immunologic reaction by binding to platelet-factor IV, presenting as heparin-induced thrombocytopenia, remains as a side effect. For more than 60 years heparin has been the immediate anticoagulant of choice in many clinical indications. Further development of heparins resulted in the production of low-molecular weight heparins and Fondaparinux, which substituted heparin for many indications and has received many more new indications, including administration for non-anticoagulant purposes. This development is still ongoing and has resulted in more than 300 registered clinical trials at the end of 2015. All types of heparins are still investigated in patients with impairment of renal function to improve the safety of treatment. New therapeutic strategies for the prevention and treatment of thromboembolism, as well as of the non-anticoagulant actions of natural and modified types of heparins, are studied intensively. The clinical study designs include treatment with vitamin-K and non-vitamin K oral anticoagulants. Consequently, heparins, low-molecular weight heparins and Fondaparinux play an important role in the human health care system.
    Mesh-Begriff(e) Anticoagulants/administration & dosage ; Anticoagulants/adverse effects ; Clinical Trials as Topic ; Drug Design ; Heparin/administration & dosage ; Heparin/adverse effects ; Heparin, Low-Molecular-Weight/administration & dosage ; Heparin, Low-Molecular-Weight/adverse effects ; Humans ; Polysaccharides/administration & dosage ; Polysaccharides/adverse effects ; Renal Insufficiency/drug therapy ; Renal Insufficiency/physiopathology ; Thromboembolism/drug therapy ; Thromboembolism/physiopathology ; Vitamin K/administration & dosage
    Chemische Substanzen Anticoagulants ; Heparin, Low-Molecular-Weight ; Polysaccharides ; Vitamin K (12001-79-5) ; Heparin (9005-49-6) ; fondaparinux (J177FOW5JL)
    Sprache Englisch
    Erscheinungsdatum 2016-06
    Erscheinungsland Netherlands
    Dokumenttyp Journal Article ; Review
    ZDB-ID 779519-1
    ISSN 1874-1754 ; 0167-5273
    ISSN (online) 1874-1754
    ISSN 0167-5273
    DOI 10.1016/S0167-5273(16)12003-0
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patients.

    Harenberg, Job

    Thrombosis research

    2016  Band 140 Suppl 1, Seite(n) S165–7

    Abstract: A two-fold prolongation of activated partial thromboplastin time (APTT) is established as therapeutic range for therapy with unfractionated heparin, hirudin and argatroban. The international normalized ratio (INR) of 2 to 3 is required to maintain ... ...

    Abstract A two-fold prolongation of activated partial thromboplastin time (APTT) is established as therapeutic range for therapy with unfractionated heparin, hirudin and argatroban. The international normalized ratio (INR) of 2 to 3 is required to maintain anticoagulation in the therapeutic range of vitamin K antagonists. The therapeutic range of anti-factor Xa activity during therapy with low-molecular weight heparins and danaparoid are less well and of direct oral anticoagulants (DOAC) poorly defined. The relation of aPTT and INR values to thrombotic and bleeding events are well established despite a large variation of values in affected patients. The relation of coagulation values of the other anticoagulants to clinical events is open. The value of determination in cancer patients is higher because of the increased risk for thrombotic and bleeding events of this patient group. Several activities are currently undertaken to certify methods for in vitro diagnostic testing for DAOCs.
    Mesh-Begriff(e) Anticoagulants/pharmacology ; Anticoagulants/therapeutic use ; Blood Coagulation Tests ; Dabigatran/pharmacology ; Dabigatran/therapeutic use ; Drug Monitoring ; Factor Xa Inhibitors/pharmacology ; Factor Xa Inhibitors/therapeutic use ; Hemorrhage/chemically induced ; Heparin, Low-Molecular-Weight/pharmacology ; Heparin, Low-Molecular-Weight/therapeutic use ; Humans ; International Normalized Ratio ; Neoplasms/complications ; Partial Thromboplastin Time ; Pyrazoles/pharmacology ; Pyrazoles/therapeutic use ; Pyridones/pharmacology ; Pyridones/therapeutic use ; Rivaroxaban/pharmacology ; Rivaroxaban/therapeutic use ; Thrombosis/etiology ; Thrombosis/prevention & control ; Warfarin/pharmacology ; Warfarin/therapeutic use
    Chemische Substanzen Anticoagulants ; Factor Xa Inhibitors ; Heparin, Low-Molecular-Weight ; Pyrazoles ; Pyridones ; apixaban (3Z9Y7UWC1J) ; Warfarin (5Q7ZVV76EI) ; Rivaroxaban (9NDF7JZ4M3) ; Dabigatran (I0VM4M70GC)
    Sprache Englisch
    Erscheinungsdatum 2016-04
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 121852-9
    ISSN 1879-2472 ; 0049-3848
    ISSN (online) 1879-2472
    ISSN 0049-3848
    DOI 10.1016/S0049-3848(16)30117-7
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang